The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth.
The quinoxaline anti-tumor agent (R+)XK469 mediates its effects by topoisomerase IIB inhibition. This report describes a 14-year old with relapsed neuroblastoma who experienced disease stabilization for 14 months while receiving (R+)XK469 monotherapy. Due to this favorable response, laboratory studies were undertaken to determine efficacy in the preclinical setting. (R+)XK469 inhibited proliferation, caused G(2) cell cycle arrest of neuroblastoma cells in vitro, and inhibited growth of neuroblastoma xenograft tumors. These preclinical results, coupled with the favorable clinical response, demonstrate that (R+)XK469 and similar anti-tumor agents may be effective in the treatment of high-risk neuroblastoma and warrant further testing.
Kakodkar
Nisha C
NC
Department of Pediatrics, University of Chicago, Chicago, Illinois, USA.
Peddinti
Radhika
R
Kletzel
Morris
M
Tian
Yufeng
Y
Guerrero
Lisa J
LJ
Undevia
Samir D
SD
Geary
David
D
Chlenski
Alexandre
A
Yang
Qiwei
Q
Salwen
Helen R
HR
Cohn
Susan L
SL
D000293:Adolescent; D000970:Antineoplastic Agents / Q000494:pharmacology; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects*; D017809:Fatal Outcome; D006801:Humans; D009362:Neoplasm Metastasis; D009447:Neuroblastoma / Q000188:drug therapy* / Q000473:pathology; D011810:Quinoxalines / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D011810:Quinoxalines; C118180:XK 469